FrancophonIA/ELRC3.0 huggingface dataset:
English: Yttrium (90Y) has a half-life of 2.67 days (64.1 hours).
Croatian: Itrij (90Y) ima vrijeme poluraspada od 2,67 dana (64,1 sat).
English: Liver uptake decreases then to 8.4 % 24 hours after injection.
Croatian: Apsorpcija u jetri zatim se smanjuje na 8,4% 24 sata nakon injekcije.
English: The chelating efficacy is greatest immediately or within one hour of exposure when the radionuclide is circulating in or available to tissue fluids and plasma.
Croatian: Djelotvornost kelacije najveća je neposredno ili unutar jednoga sata od izlaganja kada je radionuklid u cirkulaciji ili je dostupan u tekućinama u tkivima i plazmi.
English: In bone, percentage of injected activity increases from 3.1 % at 5 min to 18 % at 6 hours and then decreases with time.
Croatian: U kostima, postotak primijenjene aktivnosti povećava se s 3,1% nakon 5 min na 18% nakon 6 sati, a zatim s vremenom opada.
English: The administration of radioactive medicinal products creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc.
Croatian: Primjena radioaktivnih lijekova stvara rizik za druge osobe od vanjskog zračenja ili kontaminacije prolivenim urinom, povraćanjem, itd.
English: Activity measurements using an ionisation chamber are very sensitive to geometric factors and, therefore, should be performed only under geometric conditions which have been appropriately validated.
Croatian: Mjerenja aktivnosti korištenjem ionizacijske komore izrazito su osjetljiva na geometrijske faktore, te ih stoga treba obavljati samo pod prikladno validiranim geometrijskim uvjetima.
English: There are no data available on the toxicity of Yttrium (90Y) chloride nor on its effects on reproduction in animals or its mutagenic or carcinogenic potential.
Croatian: Nema dostupnih podataka o toksičnosti itrijeva (90Y) klorida niti njegovim učincima na reprodukciju u životinja, ili njegov mutageni ili kancerogeni potencijal.
English: Appropriate aseptic precautions should be taken, complying with the requirements of Good Pharmaceutical Manufacturing Practice, in order to maintain the sterility of Yttriga and to maintain sterility throughout the labelling procedures.
Croatian: Potrebno je pridržavati se prikladnih mjera predostrožnosti u pogledu aseptičnosti, u skladu sa zahtjevima dobre farmaceutske proizvođačke prakse, kako bi se zadržala sterilnost lijeka Yttriga i sterilnost tijekom procesa označavanja.
English: The activity administered must be such that the resulting radiation dose is as low as reasonably achievable bearing in mind the need to obtain the intended therapeutic result.
Croatian: Primijenjena aktivnost mora biti takva da je rezultirajuća doza zračenja što manja moguća, uzimajući u obzir potrebu da se postigne željeni terapijski rezultat.
English: Usual precautions regarding sterility and radioactivity should be respected.
Croatian: Potrebno je pridržavati se uobičajenih mjera predostrožnosti u pogledu sterilnosti i radioaktivnosti.
English: Please tell your doctor if there is any possibility that you are pregnant.
Croatian: Molimo obavijestite svog liječnika o mogućoj trudnoći.
English: Your doctor will not administer Yttriga directly.
Croatian: Vaš liječnik neće lijek Yttriga primijeniti izravno.
English: When the target is reached, Yttriga gives tiny radiation doses to these specific sites.
Croatian: Nakon što dosegne metu, Yttriga otpušta malene doze zračenja na tim određenim mjestima.
English: 4.6 Fertility, pregnancy and lactation
Croatian: 4.6 Trudnoća i dojenje
English: INFORMATION IN BRAILLE Justification for not including Braille accepted
Croatian: Prihvaćeno obrazloženje za ne navođenje Braillea
English: The dosimetry estimates were based on a rat distribution study and the calculations were effected in accordance with MIRD/ICRP 60 recommendations.
Croatian: Dozimetrijske procjene temelje se na studiji distribucije kod štakora, a izračuni su napravljeni u skladu s preporukama MIRD/ICRP 60.
English: Before administering a radioactive medicinal product to a mother who is breast-feeding, consideration should be given to whether the investigation could be reasonably delayed until the mother has ceased breast-feeding.
Croatian: Prije davanja radioaktivnog lijeka majci koja doji, potrebno je razmotriti može li se davanje razumno odgoditi dok majka ne prestane dojiti.
English: Cal.: {DD/MM/YYYY} (12h CET)
Croatian: Kal.: {DD/MM/GGGG} (12h CET)
English: • CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON
Croatian: • UVJETI ILI OGRANIČENJA VEZANA UZ OPSKRBU I UPORABU LIJEKA ZADANI
English: Yttriga is administered after being combined with another medicine by your doctor under strictly controlled conditions.
Croatian: Yttriga se primjenjuje nakon kombiniranja s drugim lijekom od strane liječnika u strogo kontroliranim uvjetima.
English: Radiopharmaceuticals should be prepared by the user in a manner which satisfies both radiation safety and pharmaceutical quality requirements.
Croatian: Radiofamaceutike korisnik mora pripremiti na način koji zadovoljava i sigurnost od radijacije i zahtjeve farmaceutske kvalitete.
English: Yttrium (90Y) is a beta pure emitter.
Croatian: Itrij (90Y) je čisti beta emiter.
English: Radiopharmaceuticals should be received, used and administered only by authorised persons in designated clinical settings and receipt, storage, use, transfer and disposal are subject to the regulations and appropriate licences of the competent authorities.
Croatian: Radiofarmaceutike smije zaprimati, koristiti i pacijentima davati samo ovlaštene osobe u odobrenim kliničkim uvjetima, a prijem, skladištenje, uporaba, transfer i odlaganje moraju se obavljati sukladno propisima i odgovarajućim dozvolama nadležnih tijela.
English: Radiopharmaceutical precursor - Not intended for direct use in patients.
Croatian: Radiofarmaceutski prekursor - Nije namijenjeno za izravnu primjenu pacijentima.
English: What Yttriga is and what it is used for Before you use Yttriga How to use Yttriga.
Croatian: Što je Yttriga i za što se koristi Prije nego primite lijek Yttriga Kako koristiti lijek Yttriga
English: Pharmacotherapeutic group: Other therapeutic radiopharmaceuticals, ATC code: V10X.
Croatian: Farmakoterapijska skupina: Ostali terapijski radiofarmaceutici, ATK oznaka: V10X.
English: - Because there are strict laws covering the use, handling and disposal of radiopharmaceuticals, Yttriga will always be used in a hospital or a similar setting.
Croatian: - Zbog postojanja strogih zakona za primjenu, rukovanje i odlaganje radiofarmaceutika, Yttriga se uvijek mora koristiti u bolnicama ili sličnom okruženju.
English: Exposure to ionising radiation is linked with cancer induction and a potential for development of hereditary defects.
Croatian: Izloženost ionizirajućem zračenju povezana je s nastankom raka i potencijalom za razvoj nasljednih grešaka.
English: Dose Your physician will decide on the amount of Yttriga, which you will receive for the treatment.
Croatian: Liječnik će odlučiti o količini lijeka Yttriga koju ćete primiti tijekom liječenja.
English: The radiation dose resulting from therapeutic exposure may result in higher incidence of cancer and mutations.
Croatian: Doza zračenja do koje dolazi zbog terapijske izloženosti može rezultirati povećanom incidencijom raka i mutacija.
English: Absorbed dose per unit activity administered (mGy/MBq)
Croatian: Apsorbirana doza po primijenjenoj jedinici aktivnosti (mGy/MBq)
English: Take special care with Yttriga - Yttriga is a radioactive medicine and is only used in combination with another medicinal product.
Croatian: Budite posebno oprezni s lijekom Yttriga - Yttriga je radioaktivni lijek i koristi se samo u kombinaciji s drugim lijekom.
English: The volume is 0.02-3 ml.
Croatian: Volumen iznosi 0,02-3 ml.
English: The vial may contain high pressure due to radiolysis.
Croatian: Bočica može biti pod visokim tlakom zbog radiolize.
English: The theoretical specific activity is 20 GBq/microgram of Yttrium (90Y) (see section 6.5).
Croatian: Teoretska specifična aktivnost je 20 GBq/mikrogramu itrija (90Y) (vidjeti dio 6.5).
English: The volume is 0.02-5 ml.
Croatian: Volumen iznosi 0,02-5 ml.
English: The two main organs where Yttrium (90Y) chloride distributes are the liver and bones.
Croatian: Dva glavna organa u kojima se distribuira itrijev (90Y) klorid su jetra i kosti.
English: It decays by emission of beta radiation of 2.281 MeV (99.98 %) of maximal energy to stable Zirconium (90Zr).
Croatian: Itrij se emitirajući beta zračenje maksimalne energije 2,281 MeV (99,98 %) raspada u stabilni cirkonij (90Zr).
English: Your doctor will ask you to stop breast-feeding.
Croatian: Dojenje Liječnik će od Vas tražiti da prestanete dojiti.
English: If the administration cannot be delayed, a lactating mother should be advised to stop breast-feeding.
Croatian: Ako se davanje lijeka ne može odgoditi, majku koja doji treba upozoriti da prestane dojiti.
English: Women of childbearing potential should use effective contraception during and after treatment.
Croatian: Žene u reproduktivnoj dobi moraju koristiti učinkovitu kontracepciju tijekom i nakon liječenja.
English: At 1 and 24 hours, blood radioactivity decreases from 11.0 % to 0.14 % of the administered activity.
Croatian: radioaktivnost krvi smanjuje se s 11,0% na 0,14% primijenjene aktivnosti.
English: It is important that all glassware, syringe needles etc, used for the preparation of the radiolabelled medicinal product are thoroughly cleaned to ensure freedom from such trace metal impurities.
Croatian: Vrlo je važno da se sav stakleni pribor, igle itd. koji se koristi za pripremu radioaktivno označenog lijeka temeljito očisti kako bi se osiguralo da nema onečišćenja uzrokovanih metalima u tragovima.
English: Any unused product or waste material should be disposed of in accordance with local requirements.
Croatian: Neiskorišteni proizvod ili otpadni materijal mora se zbrinuti u skladu s lokalnim propisima.
English: Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu
Croatian: Detaljne informacije o ovom proizvodu dostupne su na internetskoj stranici Europske agencije za lijekove http://www.ema.europa.eu.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Croatian: Detaljne informacije o ovom lijeku dostupne su na internetskoj stranici Europske agencije za lijekove: http://www.ema.europa.eu/.
English: Gastro-intestinal content
Croatian: Gastrointestinalni sadržaj
English: Hydrochloric acid (0.04 M)
Croatian: Kloridna kiselina (0,04 M)
English: SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN
Croatian: POSEBNO UPOZORENJE DA LIJEK TREBA ČUVATI IZVAN DOHVATA
English: Radiation protection precautions in accordance with national regulations must therefore be taken.
Croatian: Potrebno je poduzeti mjere zaštite od zračenja u skladu s nacionalnim propisima.
English: Deutschland
Croatian: Njemačka
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 19/01/2006
Croatian: Datum prvog odobrenja: 19.01.2006.
English: To be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide.
Croatian: Lijek se koristi isključivo za radiološko označavanje molekula nosača, koje su posebno razvijene i ovlaštene za radioaktivno označavanje ovim radionuklidom.
English: In the rat, following intravenous administration, Yttrium (90Y) chloride is rapidly cleared from the blood.
Croatian: U štakora se, nakon intravenske primjene, itrij (90Y) klorid brzo uklanja iz krvi.
English: For each patient, exposure to ionising radiation must be justifiable on the basis of likely clinical benefit.
Croatian: izlaganje ionizirajućem zračenju mora biti opravdano na osnovi moguće kliničke koristi.
English: However, a post-exposure interval > 1 hour does not preclude the administration and effective action of chelator with reduced efficiency.
Croatian: Ipak, vremenski interval veći od 1 sata nakon izlaganja ne isključuje davanje i učinkovitost sredstva za kelaciju koja je u tom slučaju smanjena.
English: Yttrium (90Y) chloride is produced by decay of its radioactive precursor Strontium (90Sr).
Croatian: Itrijev (90Y) klorid nastaje raspadanjem njegovog radioaktivnog prekursora stroncija (90Sr).
English: It will only be handled and administered by people who are trained and qualified in the safe handling of radioactive material.
Croatian: Sredstvom mora rukovati i primjenjivati ga samo osoblje koje je obučeno i ovlašteno za sigurno rukovanje radioaktivnim materijalom.
English: • CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Croatian: • UVJETI ILI OGRANIČENJA VEZANA UZ SIGURNU I DJELOTVORNU
English: These chelating agents suppress yttrium radiotoxicity by an exchange between the calcium ion and the yttrium due to their capacity of forming water soluble complexes with the chelating ligands (DTPA, EDTA).
Croatian: Ovi pripravci za kelaciju zatomljuju radioaktivnu toksičnost itrija razmjenom između iona kalcija i itrija zbog svoje sposobnosti za tvorbu kompleksa topivih u vodi pomoću kelacijskih liganda (DTPA,
English: Adult (70 kg)
Croatian: Odrasli (70 kg)
English: Stomach
Croatian: Želudac
English: 1 g of the chelating agents should be administered by slow intravenous injection over 3 - 4 minutes or by infusion (1 g in 100 - 250 ml of dextrose, or normal saline).
Croatian: 1 g sredstva za kelaciju treba dati pacijentu sporom intravenoznom injekcijom tijekom 3 - 4 minute ili infuzijom (1 g na 100 - 250 ml dekstroze ili normalne fiziološke otopine).
English: Act.: (Y) GBq/vial
Croatian: Akt.: (Y) GBq/bočica
English: Pregnancy Yttrium (90Y)-labelled medicinal products are contraindicated in established or suspected pregnancy or when pregnancy has not been excluded (see section 4.3).
Croatian: Lijekovi radioaktivno označeni itrijem (90Y) kontraindicirani su u slučaju ustanovljene trudnoće, kada se sumnja na trudnoću, ili kada se trudnoća ne može isključiti (vidjeti dio 4.3).
English: THE MARKETING AUTHORISATION HOLDER Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2)
Croatian: Lijek se izdaje na ograničeni recept (Vidjeti Dodatak I: Sažetak opisa svojstava lijeka, dio 4.2)
English: If Yttriga is administered inadvertently
Croatian: Ako se nehotično primijeni Yttriga
English: ANNEX II A. MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE
Croatian: DODATAK II A. PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE LIJEKA U PROMET
English: BEFORE YOU USE YTTRIGA
Croatian: PRIJE NEGO PRIMITE LIJEK YTTRIGA
English: MARKETING AUTHORISATION NUMBER(S) EU/1/05/322/001 (3 ml V-shaped vial) EU/1/05/322/002 (10 ml flat bottom vial)
Croatian: EU/1/05/322/001 (bočica od 3 ml u obliku slova V) EU/1/05/322/002 (bočica od 10 ml s ravnim dnom)
English: Radiolabelling of medicinal products, such as monoclonal antibodies, peptides or other substrates, with Yttrium (90Y) chloride is very sensitive to the presence of trace metal impurities.
Croatian: Radioaktivno označavanje lijekova kao što su monoklonska antitijela, peptidi i drugi supstrati itrijevim (90Y) kloridom vrlo je osjetljivo na prisutnost onečišćenja u obliku metala u tragovima.
English: The vial may contain high pressure due to radiolysis (see section 12).
Croatian: 6.6 Posebne mjere za zbrinjavanje Bočica može biti pod visokim tlakom zbog radiolize (vidjeti dio 12).
English: The product should be aseptically withdrawn through the stopper using sterilised single use needle and syringe after disinfecting the stopper.
Croatian: Proizvod se kroz čep mora aseptički izvući koristeći steriliziranu iglu i štrcaljku nakon dezinfekcije čepa.
English: No interactions of Yttrium (90Y) chloride with other medicines are known as no clinical studies are available.
Croatian: Interakcije itrijeva (90Y) klorida s drugim lijekovima nisu poznate i o njima nema dostupnih kliničkih studija.
English: Colourless clear sterile solution.
Croatian: Bezbojna, bistra sterilna otopina.
English: Women of childbearing potential Women of childbearing potential have to use effective contraception during and after treatment.
Croatian: Žene u reproduktivnoj dobi Žene u reproduktivnoj dobi moraju primjenjivati učinkovite metode kontracepcije tijekom i nakon liječenja.
English: Therefore, in case of an inadvertent administration of Yttriga, the radiotoxicity for the patient must be reduced by immediate (i. e. within 1 hour) administration of preparations containing chelators like CaDTPA or Ca-EDTA in order to increase the elimination of the radionuclide from the body.
Croatian: Zbog toga u slučajevima nehotične primjene lijeka Yttriga, radioaktivnu toksičnost u pacijenta mora se odmah (tj. unutar 1 sata) smanjiti davanjem pripravaka za kelaciju koji sadrže Ca-DTPA ili Ca-EDTA
English: INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS Before use, packaging and radioactivity should be checked.
Croatian: Prije uporabe potrebno je provjeriti pakovanje i radioaktivnost.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU I UNUTARNJEM PAKOVANJU
English: HOW TO USE YTTRIGA
Croatian: KAKO KORISTITI LIJEK YTTRIGA
English: Yttriga is intended for radiolabelling of medicinal products to treat specific diseases, which are subsequently administered by approved route.
Croatian: Yttriga je namijenjena za radioaktivno označavanje lijekova namijenjenih liječenju određenih bolesti koji se naknadno primjenjuju odobrenim putem.
English: Clear colourless solution, free of particulate matter.
Croatian: Bistra bezbojna otopina bez čestica.
English: METHOD OF ADMINISTRATION in vitro labelling
Croatian: NAČIN PRIMJENE LIJEKA označavanje in vitro
English: The contents of the vial of Yttriga is not to be administered directly to the patient but must be used for the radiolabelling of carrier molecules, such as monoclonal antibodies, peptides or other substrates.
Croatian: 4.4 Posebna upozorenja i mjere opreza pri uporabi Sadržaj bočice lijeka Yttriga ne smije se dati izravno pacijentu, već se mora upotrijebiti za radioaktivno označavanje molekula nosača, kao što su monoklonska antitijela, peptidi ili drugi supstrati.
English: MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS VIAL
Croatian: PODACI KOJE MORAJU NAJMANJE SADRŽAVATI MALE UNUTARNJE JEDINICE PAKOVANJA
English: For further information regarding the treatment and possible effects caused by the radiolabelled medicinal product, please refer to the package leaflet of the medicinal product used as combination partner.
Croatian: Za daljnje informacije o liječenju i mogućim nuspojavama uzrokovanima radioaktivno označenim lijekovima, molimo pročitajte uputu o lijeku u pakiranju lijeka koji se koristi u kombinaciji.
English: Yttriga is intended for in vitro labelling of medicinal products which are subsequently administered by the approved route.
Croatian: Yttriga je namijenjena za in vitro označavanje lijekova koji se naknadno primjenjuju odobrenim putem.
English: Specific activity at calibration: (Y) GBq/vial
Croatian: Specifična aktivnost pri kalibriraciji: (Y) GBq/bočica POPIS POMOĆNIH TVARI
English: Possible side effects How to store Yttriga Further information
Croatian: Kako čuvati lijek Yttriga Dodatne informacije
English: The toxicity of the free Yttrium (90Y) due to in-vivo release from the labelled biomolecule in the body during therapy could be reduced by post-administration of chelating agents.
Croatian: Toksičnost slobodnoga itrija (90Y) uslijed in vivo otpuštanja u tijelo iz označenih biomolekula tijekom terapije može se smanjiti naknadnim davanjem sredstava za kelaciju.
English: Storage should be in accordance with local regulations for radioactive substances.
Croatian: Čuvanje treba biti u skladu s lokalnim propisima za radioaktivne tvari.
English: Do not use Yttriga after the expiry date and time which is stated on the label after EXP.
Croatian: Yttriga se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na naljepnici nakon oznake „Rok valjanosti“.
English: Yttriga is a radioactive medicine used in combination with another medicine which targets specific body cells.
Croatian: ŠTO JE YTTRIGA I ZA ŠTO SE KORISTI Yttriga je radioaktivni lijek koji se koristi u kombinaciji s drugim lijekom koji se ciljano veže na određene stanice u tijelu.
English: CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT Vol.: {Z} ml
Croatian: ROK VALJANOSTI Rok valjanosti (12h CET) BROJ SERIJE Broj serije SADRŽAJ PO TEŽINI, VOLUMENU ILI BROJU JEDINICA LIJEKA Vol.: {Z} ml
English: - The other ingredient is hydrochloric acid (0.04 M).
Croatian: - Pomoćna tvar je kloridna kiselina (0,04 M).
English: This leaflet was last revised in {MM/YYYY}.
Croatian: Uputa je zadnji put odobrena u
English: Colourless type I glass vial of 3 ml with a V-shapped bottom or a colourless type I glass vial of 10 ml with a flat bottom with a silicon stopper, closed with an aluminium seal.
Croatian: Staklena bočica od bezbojnog stakla tip I od 3 ml s dnom u obliku slova V, ili staklena bočica od bezbojnog stakla tip
English: HOW TO STORE YTTRIGA
Croatian: KAKO ČUVATI LIJEK YTTRIGA
English: 1 year (10 kg)
Croatian: 1 godina (10 kg)
English: Store in accordance with local regulations for radioactive substances.
Croatian: Čuvati u skladu s lokalnim propisima za radioaktivne tvari.
English: NOT INTENDED FOR DIRECT APPLICATION TO PATIENTS
Croatian: NIJE NAMIJENJENO ZA IZRAVNU PRIMJENU PACIJENTIMA
English: The presence of free Yttrium (90Y) chloride in the body after an inadvertent administration of Yttriga will lead to increased bone marrow toxicity and haematopoietic stern cell damage.
Croatian: 4.9 Predoziranje Prisutnost itrijeva (90Y) klorida u tijelu nakon nehotične primjene lijeka Yttriga rezultirat će povećanom toksičnošću koštane srži i oštećenjem krvotvornih matičnih stanica.
English: Eckert & Ziegler Radiopharma GmbH Branch Braunschweig Gieselweg 1
Croatian: Eckert & Ziegler Radiopharma GmbH Podružnica Braunschweig Gieselweg 1
English: Do not administer Yttriga directly to the patient.
Croatian: Yttriga se ne smije primijeniti izravno pacijentu.
English: 5 years (17 kg)
Croatian: 5 godina (17 kg)
English: 15 years (50 kg)
Croatian: 15 godina (50 kg)
English: METHOD OF ADMINISTRATION For in vitro radiolabelling.
Croatian: NAČIN PRIMJENE LIJEKA Za radioaktivno označavanje in vitro.
English: The quantity of Yttriga required for radiolabelling and the quantity of Yttrium (90Y)-labelled medicinal product that is subsequently administered will depend on the medicinal product radiolabelled and its intended use.
Croatian: Količina lijeka Yttriga potrebna za radioaktivno označavanje i količina lijeka označenog itrijem (90Y) koja se naknadno primjenjuje ovisi o lijeku koji se radioaktivno označava i o njegovoj namjeni.
English: - if you are allergic (hypersensitive) to Yttrium (90Y) chloride or any of the other ingredients of
Croatian: Ne koristite lijek Yttriga: - ako ste alergični (preosjetljivi) na itrijev (90Y) klorid ili bilo koji drugi sastojak lijeka Yttriga.
English: 10 years (30 kg)
Croatian: 10 godina (30 kg)
English: Yttriga is only to be used by specialists experienced with in vitro radiolabelling.
Croatian: 4.2 Doziranje i način primjene Lijek Yttriga smiju koristiti samo specijalisti s iskustvom u radioaktivnom označavaju in vitro.
English: - The active substance is Yttrium (90Y) chloride.
Croatian: Što Yttriga sadrži - Aktivna tvar je itrijev (90Y) klorid.
English: It is not intended for direct use in patients.
Croatian: Nije namijenjena za izravnu primjenu pacijentima.
English: PHARMACEUTICAL FORM AND CONTENTS Radiopharmaceutical precursor, solution.
Croatian: OBLIK I SADRŽAJ Radiofarmaceutski prekursor, otopina.
English: METHOD AND ROUTE(S) OF ADMINISTRATION For in vitro radiolabelling.
Croatian: NAČIN I PUT(EVI) PRIMJENE LIJEKA Za radioaktivno označavanje in vitro.